FDA Sticks With Suffixes On Biosimilar Names
Biosimilar names will have to include meaningless suffixes, the U.S. Food and Drug Administration said in final guidance Thursday, brushing off concerns about confusion....To view the full article, register now.
Already a subscriber? Click here to view full article